| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 08/04/2005 | US20050171286 Copolymer-1 improvements in compositions of copolymers |
| 08/04/2005 | US20050171212 Potentiation with zeaxanthin; imparting yellowish color prior to administering light activated drugs; wet (exudative) macular degeneration |
| 08/04/2005 | US20050171206 sodium, potassium, magnesium, calcium and arginine salts of phenylbutyrate; treatment of spinal muscular atrophy; an autosomal recessive condition |
| 08/04/2005 | US20050171194 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions |
| 08/04/2005 | US20050171172 platelet derived growth factor receptor; anticarcinogenic; leukemia; specific kinase inhibitors; accurate targeting with limited inhibition of other pathways; reduced toxicity |
| 08/04/2005 | US20050171171 colony-stimulating factor receptor (c- FMS)-like tyrosine kinase 3; anticarcinogenic; leukemia;specific kinase inhibitors; accurate targeting with limited inhibition of other pathways; reduced toxicity |
| 08/04/2005 | US20050171167 Infusion fluid with a buffer and a pH-adjusting base; low pH differential reduces acid-catalyzed hydrolysis for enhanced stability; anticancer; antihyperproliferative; kit |
| 08/04/2005 | US20050171118 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis |
| 08/04/2005 | US20050171115 conditions ameliorated by monoamine reuptake; vasomotor symptoms; 4-[1-(3-chlorophenyl)-2-piperazin-1-ylethyl]tetrahydro-2H-pyran-4-ol; antidepressantp; sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome; nervous system disorders |
| 08/04/2005 | US20050171072 Therapeutic combinations and methods including IRM compounds |
| 08/04/2005 | US20050171061 Phenylsulfanylphenyl and phenyloxyphenyl substituted piperazine compounds; glycine transport inhibitors; for the treatment of psychoses and convulsive disorders: epilepsy, spasticity, and myoclonus |
| 08/04/2005 | US20050171019 Administering an exendin modified with a polymer such as polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes |
| 08/04/2005 | US20050170440 Treatment and diagnosis of insulin-resistant states |
| 08/04/2005 | US20050169994 Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| 08/04/2005 | US20050169907 amino acid sequence peptide is derived from the N' terminus region of the 50 Kd subunit of heparanase; used in drug screening for antibody as enzyme inhibitors; antitumor agents, anticarcinogenic agents, antiinflammatory agents; autoimmune disease and kidney urogenital disorder |
| 08/04/2005 | US20050169875 Stable cosmetic emulsion with polyamide gelling agent |
| 08/04/2005 | US20050169844 Near infrared imaging agent |
| 08/03/2005 | EP1559717A2 Oxabispidine compounds useful in the treatment of cardiac arrythmias |
| 08/03/2005 | EP1558935A2 Controlled-release compositions |
| 08/03/2005 | EP1558931A2 Analysis of pharmaceutical solubility and stability |
| 08/03/2005 | EP1558749A2 Atypical protein kinase c isoforms in disorders of the nervous system and cancer |
| 08/03/2005 | EP1558609A2 Kinase inhibitors |
| 08/03/2005 | EP1558597A2 Continuous process for the production of optically pure (s)-beta hydroxy-gamma-butyrolactone |
| 08/03/2005 | EP1558588A2 Compounds, compositions, and methods |
| 08/03/2005 | EP1558330A2 Cycle mode providing redundant back-up to ensure termination of treatment therapy in a medical device system |
| 08/03/2005 | EP1558290A2 Heat pasteurized liquids containing glucosamine |
| 08/03/2005 | EP1558282A2 Anti-cancer and anti-infectious disease compositions and methods for using same |
| 08/03/2005 | EP1558275A2 Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation |
| 08/03/2005 | EP1558271A2 Compositions that treat or inhibit pathological conditions associated with inflammatory response |
| 08/03/2005 | EP1558266A2 Treatment for reactive arthritis or bursitis |
| 08/03/2005 | EP1558261A2 Quinazolinone compositions for regulation of gene expression related to pathological processes |
| 08/03/2005 | EP1558219A1 Pharmaceutical formulation of olanzapine |
| 08/03/2005 | EP1558199A2 Therapeutic combination of carnitine and antioxidant polyphenols |
| 08/03/2005 | EP1558083A2 Compounds, compositions, and methods |
| 08/03/2005 | EP1558081A2 Method of treating functional bowel disorders |
| 08/03/2005 | EP1558080A2 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 08/03/2005 | EP1227806B1 Pharmaceutical formulation containing tolterodine and its use |
| 08/03/2005 | EP0969797B1 Oxidizing composition and uses for dyeing, permanently setting or bleaching keratin fibres |
| 08/03/2005 | EP0702719B1 Process for the sterilization of biological compositions and the product produced thereby |
| 08/03/2005 | CN1649610A Isolation, purification and structural identification of a bioactive component of a water soluble extract of a botanical species for enhancing immune, anti-inflammatory, anti-tumor and DNA repair proc |
| 08/03/2005 | CN1213020C Phenylalaninol derivatives |
| 08/03/2005 | CN1212826C Topically applied idebenone-containing agent with protective and regenerative effect |
| 08/02/2005 | US6924118 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 08/02/2005 | US6923959 Method of pre-inducing a state of immune tolerance before organ transplantation |
| 08/02/2005 | CA2362339C Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives |
| 08/02/2005 | CA2362337C Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives |
| 07/28/2005 | WO2005067968A1 Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| 07/28/2005 | WO2005051312A3 Extracorporeal pathogen reduction system |
| 07/28/2005 | WO2005051296A3 Fused ring dicationic anti-protozoan agents and their prodrugs |
| 07/28/2005 | WO2005048948A3 Urea derivatives as kinase modulators |
| 07/28/2005 | WO2005048940A3 Nutraceutical mangosteen tea |
| 07/28/2005 | WO2005046586A3 M3 muscarinic acetylcholine receptor antagonists |
| 07/28/2005 | WO2005044198A3 Process and formulation containing epothilones and analogs thereof |
| 07/28/2005 | WO2005041880A3 RhPV AS A MODEL FOR HPV-INDUCED CANCERS |
| 07/28/2005 | WO2005039502A3 Macromer-melt formulations |
| 07/28/2005 | WO2005039481A3 Oral drug delivery system |
| 07/28/2005 | WO2005034866A3 Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors |
| 07/28/2005 | WO2005034838A3 Protease inhibitors |
| 07/28/2005 | WO2005032490A3 Cyclic diamines and derivatives as factor xa inhibitors |
| 07/28/2005 | WO2005032469A3 METHODS FOR REGULATING BUD-HYPHA TRANSITION AND cAMP LEVELS IN CANDIDA ALBICANS |
| 07/28/2005 | WO2005030126A3 Adhesin-specific nanoparticles and process for using same |
| 07/28/2005 | WO2005027828A3 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| 07/28/2005 | WO2005025516A3 Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| 07/28/2005 | WO2005025512A3 Cobalamin conjugates for anti-tumor therapy |
| 07/28/2005 | WO2005025496B1 Aliphatic pyrazinoylguanidine sodium channel blockers |
| 07/28/2005 | WO2005020932A3 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| 07/28/2005 | WO2005020890A3 Multiplexed molecular beacon assay for detection of pathogens |
| 07/28/2005 | WO2005018552A3 Heparin binding proteins: sensors for heparin detection |
| 07/28/2005 | WO2005016279A3 Melks as modifiers of the rac pathway and methods of use |
| 07/28/2005 | WO2005011596A3 Bowman-birk inhibitor compositions for treatment of muscular atrophy and degenerative muscle disease |
| 07/28/2005 | WO2005009366A3 Restoring vascular function |
| 07/28/2005 | WO2005007110A9 Compositions and methods for hydrophobic drug delivery |
| 07/28/2005 | WO2005004793A3 Compositions and methods for treating coagulation related disorders |
| 07/28/2005 | WO2005002523A3 Process for preparing highly pure and free-flowing solid of 7-ethyltryptophol |
| 07/28/2005 | WO2004112724A3 Compositions for and methods for treating hiv |
| 07/28/2005 | WO2004112723A3 Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
| 07/28/2005 | WO2004110362A3 Immunotherapeutics for biodefense |
| 07/28/2005 | WO2004108067A3 Programmed drug delivery system |
| 07/28/2005 | WO2004100893A3 Methods for treatment of inflammatory diseases using ct-3 or analogs thereof |
| 07/28/2005 | WO2004100885A3 Compositions and methods for treating cancer |
| 07/28/2005 | WO2004098498A3 Indole acetic acid derivatives and their use as pharmaceutical agents |
| 07/28/2005 | WO2004093828A3 Reverse-turn mimetics and method relating thereto |
| 07/28/2005 | WO2004087060A3 Filtered backprojection algorithms for compton cameras in nuclear medicine |
| 07/28/2005 | WO2004069189A3 Methods of assessment of drug metabolizing enzymes |
| 07/28/2005 | WO2004066938A3 Method and composition for lowering cholesterol |
| 07/28/2005 | WO2004064767A3 Nitric oxide inducing agents |
| 07/28/2005 | WO2004060306A3 Anti-inflammatory medicaments |
| 07/28/2005 | WO2003103597A3 Methods of diagnosing & treating diabetes and insulin resistance |
| 07/28/2005 | WO2002055010A3 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/28/2005 | US20050165233 Continuous process for producing hydroxyazapirones by oxidation |
| 07/28/2005 | US20050165098 Local anesthetic methods and kits |
| 07/28/2005 | US20050165097 Comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist, for reversing local anesthesia |
| 07/28/2005 | US20050165074 inhibitors of protein tyrosine kinases, for preventing of cancer, cardiovascular disease, inflammation or multiple sclerosis |
| 07/28/2005 | US20050165051 Taxanes having a C7 carbonate substituent |
| 07/28/2005 | US20050165044 Use against Trypanosoma brucei rhodesiense (T.b.r.) and Plasmodium falciparum; prodrugs of these compounds can be used as oral treatment for malaria and human African trypanosomiasis; 2,7-bis-guanidino-9H-fluorene, 2,7-bis-guanidinofluoren-9-one |
| 07/28/2005 | US20050165031 1-(4-(3-(Pyridin-4-yl)propoxy)phenyl)-3-(5-tert-butylisoxazol-3-yl)urea; inhibits protein tyrosine kinases or a specific kinase or kinase class; for for treating and preventing conditions and diseases such as cancer, hematologic malignancies, cardiovascular disease, inflammation or multiple sclerosis |
| 07/28/2005 | US20050165024 Urea derivatives as kinase modulators |
| 07/28/2005 | US20050165022 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 07/28/2005 | US20050164975 Purine receptor inhibition as a therapeutic strategy in spinal cord and brain |
| 07/28/2005 | US20050164965 DNA or RNA having a modified backbone or base and a section that hybridizes to an EphrinB2 or EphB4 transcript causing gene expression inhibition; antineoplastic and antiproliferative agents can be synergistically administered with a second agent |